Literature DB >> 3384245

[Comparison of permanent cardiac pacing and cardiac pacing on demand in mixed carotid sinus syndrome. Acute- and medium-term follow-up study].

M Brignole1, M Barra, B Sartore, C Menozzi, G Lolli.   

Abstract

The aim of the study was to evaluate the importance of atrial synchronism for pacing therapy of patients with mixed carotid sinus syndrome. On 23 patients (21 m, 2 f; mean age 69 +/- 8 years) affected by symptomatic mixed carotid sinus syndrome we performed: 1) the study of ventriculo-atrial conduction, 2) the evaluation of pacemaker effect and 3) the carotid sinus massage in standing position during VVI and DVI temporary pacing. All patients received a permanent DVI pacemaker and then underwent a two-month period single-blind, randomized, cross-over study on DVI vs VVI mode. During DVI period, no syncope occurred in any patients, minor symptoms persisted in 11 (48%) of them; during VVI period syncopes recurred in 3 patients, symptoms requiring the withdrawal of VVI pacing and premature DVI reprogramming in 8, minor symptoms were observed in 17 (74%). A comparison between 14 patients who preferred DVI period (Group A) and the remaining 9 patients who had no preference for DVI and VVI period (Group B) revealed that Group A patients had a greater pacemaker effect (-34 +/- 16 mmHg vs -16 +/- 14 mmHg; p less than 0.02) and a higher prevalence of ventriculo-atrial conduction (78% vs 44%; p = 0.1), while the entity of the systolic pressure fall caused by carotid sinus massage was similar in the two groups both during VVI mode (Group A -51 +/- 16 mmHg vs Group B -56 +/- 27 mmHg) and DVI mode (Group A -38 +/- 17 mmHg vs Group B -45 +/- 17 mmHg).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1988        PMID: 3384245

Source DB:  PubMed          Journal:  G Ital Cardiol        ISSN: 0046-5968


  1 in total

Review 1.  The role of cardiac pacing in carotid sinus syndrome: a meta-analysis.

Authors:  Bing-Wei Chen; Zhi-Guang Wang; Na-Qiang Lv; Yan-Mei Cheng; Ai-Min Dang
Journal:  Clin Auton Res       Date:  2014-03-29       Impact factor: 4.435

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.